Faeth Therapeutics, Inc. $FTH

What the company doesAI summary of filing

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments through multi-node inhibition of oncogenic pathways. The company's lead product candidate is PIKTOR, an oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, currently being evaluated in Phase 2 trials for endometrial cancer with topline data expected by year-end 2026, and planned Phase 1b trials in HR+/HER2- breast cancer. The company is pre-revenue and generates no current product sales, instead funding operations through equity financing, including a $200 million private placement completed in February 2026. Beyond PIKTOR, Sensei has pipeline programs including NEAAR, targeting non-essential amino acid restriction in tumors, IEM for rare metabolic disease, and legacy conditionally active antibody programs from prior operations. [10-K 2026-03-30]

Segments: PIKTOR (serabelisib + sapanisertib), NEAAR (Non Essential Amino Acid Restriction), IEM (Inborn Errors of Metabolism), Solnerstotug (SNS-101)